Evidence map›Paper›PMID 40839962›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2025

Pharmacokinetics, mass balance, and metabolism of [

Ming Yang, Lei Diao, Shu Yan, Yan Tan, Donghui Liu, Yali Yuan, Zijian Zeng, Tao Hu, Dafang Zhong, Liyan Miao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ming YangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Lei DiaoClinical Research Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai, China.
Shu YanShanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yan TanClinical Research Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai, China.
Donghui LiuSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yali YuanShanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zijian ZengShanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Tao HuDepartment of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China; Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China.
Dafang ZhongShanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Liyan MiaoDepartment of Clinical Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China; Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China. Electronic address: miaolysuzhou@163.com.
Xingxing DiaoSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Electronic address: xxdiao@simm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SAF-189s is a promising highly selective, brain-penetrant, next-generation inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS proto-oncogene 1 (ROS1). The pharmacokinetics, mass balance, and metabolism of SAF-189s were measured in 6 healthy Chinese male participants after receiving a single oral dose of 160 mg [

Indexed as

Anaplastic Lymphoma KinaseCytochrome P-450 Enzyme SystemGastrointestinal MicrobiomeProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsAdministration, OralAdultCarbon RadioisotopesCytochrome P-450 CYP3ADrug InteractionsHalf-LifeHealthy VolunteersHumansMaleProto-Oncogene MasAnaplastic Lymphoma KinaseCarbon RadioisotopesCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemMAS1 protein, humanProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsROS1 protein, human[(14)C]SAF-189sALK/ROS1 inhibitorIntestinal floraNon–small cell lung cancerP450 enzymesSAF-189s metabolism and pharmacokinetics

Identifiers

PMID40839962
PMCPMC12597534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.